Cefuroxime
Cefuroxime is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Uncomplicated urinary tract infections caused by E. coli or K. pneumoniae (PO and IV)
- Uncomplicated skin and skin-structure infections caused by S. aureus or S. pyogenes (PO and IV) E. coli, Klebsiella spp., and Enterobacter spp. (IV)
- Impetigo (pediatric patients) (PO)
- Upper respiratory tract infections including acute otitis media, acute maxillary sinusitis, acute exacerbation of chronic bronchitis, and pharyngitis/tonsillitis (PO)
- Early Lyme disease (erythema migrans) caused by B. burgdorferi (PO)
- Lower respiratory tract infections including community-acquired pneumonia (CAP, IV)
- Septicemia caused by S. aureus, S. pneumoniae, E. coli, H. influenzae, Klebsiella spp. (IV only)
- Meningitis S. pneumoniae, H. influenzae, N. meningitidis, and S. aureus (MSSA) (IV only).
- Author’s comment: nafcillin preferred for MSSA meningitis.
- Bone and joint infections caused by MSSA (IV)
- Uncomplicated urethral and endocervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended, oral and IV)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Late Lyme arthritis
- CAP (oral cefuroxime)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --